In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...

Novartis secured an exclusive worldwide license to Abogen’s Abo2203 and options on additional RNA-platform programs, positioning mRNA-encoded biologic expression as a scalable autoimmune therapeutic ...

FHD-909 is an oral, first-in-class allosteric small molecule selectively inhibiting SMARCA2 (BRM) ATPase over SMARCA4 (BRG1), both central catalytic subunits of BAF chromatin-remodeling complexes.

Along with rising sales, GLP-1s are a major focus for R&D teams. Major pharma companies are developing new versions of the medication that are easier for patients to use, while al ...